Proactive Investors - Run By Investors For Investors

Paradigm Biopharmaceuticals director shows confidence with on-market share purchase

The company has begun discussions with International key opinion leaders for mucopolysaccharidoses (MPS) clinical trial design and site selection.
asx boards
Paradigm is focused on repurposing the drug pentosan polysulfate sodium.

Paradigm Biopharmaceuticals Ltd (ASX:PAR) director Christopher Fullerton has purchased 100,000 shares on-market for a total consideration of $118,116.

The transaction brings Fullerton’s total holding (direct and indirect) to 836,000 shares.

READ: Paradigm Biopharmaceuticals moving towards phase 2/3 MPS clinical trial

The company has begun discussions with International key opinion leaders (KOL’s) for mucopolysaccharidoses (MPS) clinical trial design and site selection.

MPS is a progressive rare disease caused by the absence or malfunctioning of lysosomal enzymes and has a severe unmet need.

Paradigm is focused on repurposing the drug pentosan polysulfate sodium in its injectable form (iPPS), a US FDA approved drug that has a long track record of safely treating inflammation.

The company is confident that a single successful phase 2/3 clinical trial will enable iPPS to be registered as a treatment for certain MPS indications.

View full PAR profile View Profile

Paradigm Biopharmaceuticals Ltd Timeline

Related Articles

Cancer cells
February 07 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
Surgery
February 21 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
word cancer under magnifying glass
May 02 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use